Abstract:Anti-thymocyte globulin (ATG) is often included in the conditioning regimen to prevent graft-versus-host disease (GVHD) in allogeneic hematopoietic cell transplantation (allo-HCT). However, the risk of virus reactivation increases significantly. We conducted a single-center prospective study to identify the optimal ATG exposure that ensures engraftment, effectively prevents acute GVHD, and reduces the risk of virus reactivation without increasing relapse of malignant diseases in haploidentical peripheral blood stem cell transplantation (haplo-PBSCT). From September 2018 to June 2020, 106 patients (median age, 32 years) with malignant hematological diseases who received haplo-PBSCT for the first time were enrolled. All patients received 10 mg/kg rabbit ATG (thymoglobulin) divided for 4 days (days -5 to -2). Pre-transplant, post-transplant, and total areas under the concentration-time curve (AUCs) of active ATG were calculated. Total AUC of active ATG was shown to be the best predictor for virus reactivation and acute GVHD of grades II to IV or grades III and IV. The optimal total AUC range of active ATG was 100 to 148.5 UE/mL/day. The median time was 14 versus 13 days (P = .184) for neutrophil engraftment and 13 versus 13 days (P = .263) for platelet engraftment in the optimal and non-optimal AUC groups, respectively. The optimal AUC group showed a lower cumulative incidence of cytomegalovirus (CMV) reactivation and persistent CMV viremia than the non-optimal AUC group: 60.6% (95% confidence interval [CI], 48.3%-73.1%) versus 77.1% (95% CI, 64.5%-87.7%; P = .016) and 31.5% (95% CI, 21.2%-45.3%) versus 56.3% (95% CI, 42.9%-70.4%; P = .007), respectively. The cumulative incidence of persistent Epstein-Barr virus (EBV) viremia in the optimal AUC group was significantly lower than the non-optimal total AUC group: 33.1% (95% CI, 22.5%-46.8%) versus 52.6% (95% CI, 39.3%-67.2%; P = .048). However, there was no difference in EBV reactivation (P = .752). Similar outcomes were observed for grade II to IV and grade III and IV acute GVHD between the two groups: 48.6% (95% CI, 36.8%-62.0%) versus 37.0% (95% CI, 24.8%-52.5%; P = .113) and 10.4% (95% CI, 4.8%-21.7%) versus 4.2% (95% CI, 1.0%-15.6%; P = .234, respectively. Relapse, non-relapse mortality, and disease-free survival demonstrated no significant differences between the two groups. But, overall survival at 2 years tended to increase in the optimal AUC group: 75.7% (95% CI, 62.4%-84.8%) versus 57.8% (95% CI, 42.4%-70.4%; P = .061). These data support an optimal active ATG exposure of 110 to 148.5 UE/mL/day in haplo-PBSCT. Individualized dosing of ATG in allo-HCT might reduce the risk of virus reactivation and effectively prevent acute GVHD simultaneously. (c) 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Prophylaxis of GVHD with ATG Before Allogeneic Stem Cells Transplantation

Antithymocyte Globulin for Graft-Versus-host Disease Prophylaxis in Hematopoietic Stem Cell Transplantation from Unrelated Donors: a Retrospective Report

Clinical Research on Prophylaxis of Agvhd in Allogeneic Stem Cell Transplantation with Anti -Human T-lymphocyte Rabbit Immunoglobulin

Two Doses of Antithymocyteglobulin As Graft-Versus-Host Disease Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation: A Multicenter Prospective Study

Clinical Analysis on Graft-Versus-host Disease in 55 Cases of Allogeneic Hematopoietic Stem Cell Transplantation

Antithymocyte Globulin Improves GVHD-free and Relapse-Free Survival in Unrelated Hematopoietic Stem Cell Transplantation.

Quality of Life of Patients after Allogeneic Hematopoietic Stem Cell Transplantation with Antihuman Thymocyte Globulin.

[Prophylactic Effect of CsA, MTX, MMF Combined with ATG on GVHD in Patients Underwent Unrelated Peripheral Blood Hematopoietic Stem Cell Transplantation].

Improvement of the quality of life by adding anti-human thymocyte globulin to the conditioning regimen

Effect Analysis of Antithymocyte Globulin Versus Antilymphocyte Globulin for Graft Versus Host Disease Prophylaxis in 102 Cases of Allogeneic Hematopoitic Stem Cell.

Anti-CD25 monoclonal antibody with antithymocytic globulin for steroid-resistant severe acute graft-versus-host disease after unrelated donor hematopoietic stem cell transplantation]

Low-Dose Anti-Thymocyte Globulin Plus Low-Dose Posttransplant Cyclophosphamide As an Effective Regimen for Prophylaxis of Graft Versus Host Disease after Haploidentical Peripheral Blood Stem Cell Transplantation with Maternal/Collateral Related Donors

Long‐term Outcomes of Antithymocyte Globulin in Patients with Hematological Malignancies Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation: a Systematic Review and Meta‐analysis

Antithymocyte Globulin for Matched Sibling Donor Transplantation in Patients With Hematologic Malignancies: A Multicenter, Open-Label, Randomized Controlled Study

Experimental study on prevention of graft-versus-host disease by selective elimination of alloreactive donor lymphocytes prior to stem cell transplantation

The prophylactic application of low-dose rabbit antithymocyte globulin in matched siblings HSCT with high-risk factors for graft-versus-host disease

Role of Antithymocyte Globulin in Matched Sibling Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies

Study on preventing and treating graft-versus-host disease in 21 cases with allogeneic peripheral blood stem cell transplantation for the treatment of leukemia

[Induction of aGVHD after allogeneic hematopoietic stem cell transplantation for refractory or relapsed acute leukemia].

Optimal Active Anti-Thymocyte Globulin Exposure Associated with Minimum Risk of Virus Reactivation and Comparable Acute Graft-Versus-Host Disease under Adult Myeloablative Haploidentical Peripheral Blood Stem Cell Transplantation.

Low-dose Post-Transplant Cyclophosphamide and Anti-Thymocyte Globulin As an Effective Strategy for GVHD Prevention in Haploidentical Patients.